Name Card
rp00258 picture

Dr Ho, James Chung Man 何重文

Title:
Clinical Associate Professor

Professional Qualifications
YearAwarding InstitutionQualification
2010Royal College of PhysiciansFRCP (Lond)
2009Royal College of Physicians of EdinburghFRCP (Edin)
2008Royal College of Physicians and Surgeons of GlasgowFRCP (Glasg)
2007The University of Hong KongMD
2001Hong Kong Academy of MedicineFHKAM (Medicine)
2001Hong Kong Academy of MedicineFHKCP
1996Royal College of PhysiciansMRCP (UK)
1993MBBS (HK)
1993The University of Hong KongMBBS (HK)
Biography

Dr. James Ho is a Clinical Associate Professor at the Department of Medicine, The University of Hong Kong. He received his medical degree (M.B.,B.S.) from The University of Hong Kong in 1993, with training in internal medicine and respiratory medicine in the Department of Medicine, Queen Mary Hospital. He obtained Doctor of Medicine from The University of Hong Kong with his thesis entitled “Non-small cell lung cancer: from bench to bedside”. He is a Specialist in Respiratory Medicine in Hong Kong, Fellow of the American College of Chest Physicians, Fellow of the Royal College of Physicians and Surgeons of Glasgow, Fellow of the Royal College of Physicians of Edinburgh and London. He underwent basic research in lung cancer biology at the Cleveland Clinic Foundation, USA from 2000-01. Among his various appointments in professional societies, he was the President of the Hong Kong Thoracic Society in 2011-13. Currently, he is a member of the Education Committee of the International Association for the Study of Lung Cancer and a board member of the Respiratory Subspecialty Board of the Hong Kong College of Physicians.

 

Dr. Ho has an established track record in lung cancer research, and the areas of focus over the years include the role of antioxidants, epidemiology, diagnostics, and management. The emphasis of recent projects is on translational research into novel lung cancer therapeutic options, and clinical trials. Based on the earlier findings on altered antioxidant expression in lung cancer tissues (Ho JC et al. Cancer Research 2001;61:8578-8585), a subsequent clinical study was conducted demonstrating the independent alterations of systemic superoxide dismutase and glutathione peroxidase levels among lung cancer subjects (Ho JC et al. Eur Respir J 2007;29:273-278). This may further enhance the understanding of the role of antioxidants in lung carcinogenesis. Lymphoepithelioma-like carcinoma (LELC) of lung has been an uncommon type of Epstein-Barr virus-related lung cancer with special interest among the Asians. Apart from being one of the pioneers in first-line systemic chemotherapy treatment for advanced LELC of lung (Ho JC et al. Respir Med 2000;94(10):943-947), Dr. Ho and his team have reported a novel clinical application of oral capecitabine as a salvage chemotherapy treatment of this uncommon type of lung cancer (Ho JC et al. J Thorac Oncol 2009;4(9):1174-1177). His clinical experience in LELC of lung has been summarized in one of the few reviews on the area (Ho JC et al. Respirology 2006;11:539-545). In recent years, targeted therapy (e.g. against epidermal growth factor receptor (EGFR)) has emerged as a promising approach in treatment of non-small cell lung cancer, though acquired resistance is almost inevitable. A recent pre-clinical study on the combination of autophagy inhibitor with erlotinib (targeted therapy against EGFR) may further improve the outcome of this treatment approach (Li YY, Lam SK, Mak JC, Zheng CY, Ho JC. Lung Cancer 2013;81(3):354-61). In addition, another recent pre-clinical model has demonstrated a synergistic combination of arsenic trioxide (available in HKU as an oral treatment for acute promyelocytic leukaemia) and cisplatin in small cell lung cancer (Zheng CY, Lam SK, Li YY, Fong BM, Mak JC, Ho JC. Lung Cancer 2013;82(2):222-30), which holds promise to improve the existing treatment.

 
Honours, Awards & Prizes
AwardeesAward DateHonours / Awards / PrizesCategory
Ng, TB
Liao, QX
2012-03-01PI: (May 2012). Investigation of therapeutic efficacy and mechanisms of polysaccharide of Dendrobium officinale in alleviating cigarette-induced pulmonary inflammation.: Innovation and Technology Support Programme, the Government of the Hong Kong Special Administrative Region. (Project code: ITS/313/11).
Research Achievement
2005-02-19Young Investigator Award 2005: 10th Medical Research Conference, The University of Hong Kong, Hong Kong, 19-20 February
Research Achievement
2010-12-011 PDF to support the projects on "Arsenic trioxide in treatment of lung cancer": 24th round PDF/RAP Scheme (Centre for Cancer Reserach) in 2010
Others
2004-03-01Young Investigator Award 2004: The 44th Annual Meeting of the Japanese Respiratory Society 2004, Tokyo, Japan. Japanese Respiratory Society
Research Achievement
2004-01-01Young Investigator Award 2004: Medical Research Conference, Department of Medicne, HKU
Research Achievement
Ng, T
Liao, X
2012-05-01PI: (March 2012). Investigation of therapeutic efficacy and mechanisms of polysaccharide of Dendrobium officinale in alleviating cigarette-induced pulmonary inflammation.: Innovation and Technology Support Programme, the Government of the Hong Kong Special Administrative Region (Project code: InP/067/12).
Research Achievement
Ho, SP
Chan, MMW
2007-02-01Best Poster - Increased oxidative stress in acute asthma exacerbation in Hong Kong Chinese asthmatics: 12th Medical Research Conference
Research Achievement
Ng, TB
Liao, XQ
2012-04-01PI: (April 2012). Investigation of Therapeutic Efficacy and Mechanisms of Polysaccharide of Dendrobium officinale in Alleviating Cigarette-Induced Pulmonary Inflammation.: Innovation and Technology Fund Internship Programme of Hong Kong (Project code: InP/066/12).
Research Achievement
2006-11-01Young Investigator Award 2006: 11th Congress of the Asian Pacific Society of Respirology. Japanese Respiratory Society/Asian Pacific Society of Respirology. 19-22 Nov 2006. Kyoto, Japan.
Research Achievement
Lo, RLK
Lam, WK
2008-01-01Best poster - Growth inhibitory activity of arsenic trioxide in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations.: 13th Medical Research Conference
Research Achievement
LI, Y
Lam, SK
ZHENG, C
2013-10-01The role of autophagy induced by tyrosine kinase inhibitors in non-small cell lung carcinoma. 15th World Conference on Lung Cancer, Australia, 27-30 October 2013. [Abstract presentation: recipient of The Simon Chan Shang Whai - IASLC - LFA Cancer Reserach Travel Award]: Journal of Thoracic Oncology
Research Achievement
Ho, JWY
2014-10-01Teaching Development Grant: The University Of Hong Kong
Teaching Accomplishment
Professional Societies
Term PeriodPositionProfessional Societies
since 2009Executive Board MemberHong Kong Lung Fundation
03/2011-03/2013PresidentHong Kong Thoracic Society
03/2009-03/2011Honorary SecretaryHong Kong Thoracic Society
03/2005-03/2009Honorary TreasurerHong Kong Thoracic Society
03/2003-03/2005Editor-in-Chief of NewsletterHong Kong Thoracic Society
since 11/2006Member of Research CommitteeAsian-Pacific Society of Respirology
since 09/2006Honorary Editorial Advisory Board Member, AsiaMIMS Respiratory Guide HK 2006/2007
since 01/2006Full MemberInternational Association for the Study of Lung Cancer
since 2008Collegiate memberRoyal College of Physicians of Edinburgh
since 2009FellowRoyal College of Physicians of Edinburgh
since 2010FellowRoyal College of Physicians of London
since 2008FellowRoyal College of Physicians and Surgeons of Glasgow
since 01/2002Fellow memberAmerican College of Chest Physician
since 2013Member of Subspecialty Board in Respiratory MedicineHong Kong College of Physicians
since 2013Member of Education CommitteeInternational Association for the Study of Lung Cancer
since 2015Member of Membership CommitteeInternational Association for the Study of Lung Cancer (IASLC)
Loading Content...Please Wait!
Loading Content...Please Wait!
Loading Content...Please Wait!
Loading Content...Please Wait!
Loading Content...Please Wait!
Loading Content...Please Wait!
Loading Content...Please Wait!